Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 65862-697

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 65862-697). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Effect Of Interacting Drugs On The Pharmacokinetics Of Venlafaxine And Active Metabolite O-desmethylvenlafaxine (odv). (Venlafaxine Fig1)

This is a drug interaction report that includes recommendations for PK fold change and 90% CI for the drug cimetane interacting with the analyte "aniatxine", "veniatxine" and "venistaxing". It suggests caution and monitoring for blood pressure in patients with hypertension, patients who are elderly or have hepatic dysfunction. The clinical significance of this drug interaction is unknown. Dose adjustment is not recommended.*

FDA Label Image

Figure 2: Effect Of Venlafaxine On The Pharmacokinetics Interacting Drugs And Their Active Metabolites. (Venlafaxine Fig2)

FDA Label Image

Figure 3: Pharmacokinetics Of Venlafaxine And Its Metabolite O-desmethylvenlafaxine (odv) In Special Populations. (Venlafaxine Fig3)

FDA Label Image

Package Label-principal Display Panel (37.5 mg (15 Capsule Bottle))

FDA Label Image

Package Label-principal Display Panel (37.5 mg Blister Carton (10 x 10 Unit-dose))

This text appears to be a combination of random letters and numbers and is not readable. Therefore, it is not possible to generate a useful description.*

FDA Label Image

Package Label-principal Display Panel -75 mg (15 Capsule Bottle) (Venlafaxine Fig6)

This is a prescription medication for Venlafaxine Hydrochloride, an extended-release capsule USP, with each capsule containing 75 mg of Venlafane hydrochloride USP. The usual dosage information is provided within the package, which contains 15 capsules. The medicine should be stored between 20°C and 25°C, and each capsule is provided separately for a different patient. The medication is distributed by Aurabindo Pharma USA, Inc., located in New Jersey, and made in India. The alphanumeric code TS/DRUGS/19/1093 is included on the package.*

FDA Label Image

Package Label-principal Display Panel (75 mg Blister Carton (10 x 10 Unit-dose))

FDA Label Image

Package Label-principal Display Panel (150 mg (15 Capsule Bottle))

This is a description of a medication called Venlafaxine Hydrochloride, which is an extended-release capsule containing 150 mg per capsule. The medication guide should be provided separately to each patient. There is also dosage information provided. The capsules should be stored at a temperature between 20°C - 25°C. It is distributed in the US by Aurabindo Pharma USA, Inc. The code TS/DRUGS/19/1093 is present with some additional information regarding printing.*

FDA Label Image

Package Label-principal Display Panel (150 mg Blister Carton (10 x 10 Unit-dose))

This is a description of Venlafaxine Hydrochloride Extended-Release Capsules USP medication. The text contains some distorted and incomplete characters, indicating that it was obtained by . The medication is intended for pharmaceutical use and comes in capsule form. The text also mentions a disposo modification and provides sopraay to each patient. Overall, due to the incomplete and incoherent characters, the description is not very useful and may not provide sufficient information.*

FDA Label Image

Chemical Structure (Venlafaxine Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.